Provider of closed system transfer devices (CSTDs) for hazardous drugs, Equashield, has announced an exclusive partnership with distributor Aagato Medical BVBA for the Belgian and Luxembourg markets.
Exclusive partnership
“We are determined to provide the strongest solutions available for protecting oncology professionals,” said Roel Geysen, CEO of Aagato Medical BVBA. “Our goal is for Equashield closed systems to become the standard for any facility in which hazardous drugs are prepared and administered. We are extremely pleased to be working with Equashield, a partner that is attentive to market needs and is the gold standard for closed systems.”
“We are pleased to see Belgium and Luxembourg taking a proactive approach to the safety of the staff that works with these hazardous drugs daily. In fact, Belgium has a reputation of using the highest quality devices on the market,” added Marino Kriheli, founder at Equashield. “Aagato Medical has extensive experience and relationships in these markets and is fortunate to be led by Roel Geysen, a pioneer of closed systems. Roel introduced CSTDs to Belgium 10 years ago — making Belgium one of the first countries to adopt CSTDs — and together with his team has been supporting the safety of nurses and hospital pharmacists. We are proud to work with such a strong partner in these markets.”
It was reported in a press release that a link has been found between exposure to hazardous drugs and an increase in the risk of adverse health effects for medical professionals. Not only can exposure occur through contact with drug residues but also through inhalation of vapours and aerosols while preparing and administering hazardous drugs.
Aagato Medical is a Belgian company that provides technologies and solutions for use in cancer care.
Equashield is a provider of a full range of manual and automated solutions to hospitals for the compounding and administration of hazardous drugs.